Pharming (PHAR) Net Income towards Common Stockholders (2020 - 2025)
Historic Net Income towards Common Stockholders for Pharming (PHAR) over the last 7 years, with Q3 2025 value amounting to $22.3 million.
- Pharming's Net Income towards Common Stockholders rose 9508.5% to $22.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$229.6 million, marking a year-over-year increase of 444.68%. This contributed to the annual value of -$233.0 million for FY2024, which is 463.71% down from last year.
- Per Pharming's latest filing, its Net Income towards Common Stockholders stood at $22.3 million for Q3 2025, which was up 9508.5% from -$10.0 million recorded in Q2 2025.
- In the past 5 years, Pharming's Net Income towards Common Stockholders registered a high of $22.3 million during Q3 2025, and its lowest value of -$227.2 million during Q4 2024.
- Moreover, its 5-year median value for Net Income towards Common Stockholders was -$174.9 million (2021), whereas its average is -$107.9 million.
- In the last 5 years, Pharming's Net Income towards Common Stockholders skyrocketed by 12991.11% in 2021 and then plummeted by 10873166.02% in 2022.
- Pharming's Net Income towards Common Stockholders (Quarter) stood at $15.0 million in 2021, then crashed by 1576.87% to -$221.4 million in 2022, then fell by 1.89% to -$225.6 million in 2023, then fell by 0.68% to -$227.2 million in 2024, then skyrocketed by 109.8% to $22.3 million in 2025.
- Its Net Income towards Common Stockholders stands at $22.3 million for Q3 2025, versus -$10.0 million for Q2 2025 and -$14.7 million for Q1 2025.